CellCept, Mycophenolate
CellCept, Mycophenolate Newswire

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 33 in CellCept, Mycophenolate (generic)

  1. Recent advances in autoimmune pancreatitisRead the original story

    Sunday Jun 28 | GastroHep.com

    Autoimmune pancreatitis is a form of chronic pancreatitis that is characterized clinically by frequent presentation with obstructive jaundice, histologically by a dense lymphoplasmacytic infiltrate with fibrosis, and therapeutically by a dramatic response to corticosteroid therapy. Dr Suresh Chan and colleagues from Minnesota, USA investigate the 2 disease types as well as recent advances in autoimmune pancreatiisis.


  2. mycophenolate mofetilRead the original story w/Photo

    Jun 2, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.


  3. Donald Hricik, MD, Receives AST Lifetime Achievement AwardRead the original story

    May 18, 2015 | PRWeb

    The American Society of Transplantation awarded its highest honor, the Lifetime Achievement Award, to Donald Hricik, MD, at the recent American Transplant Congress. Dr. Hricik has moved the field forward through both his involvement in clinical trials that have shaped our care of transplant patients and through his education of the next generation of transplant professionals.


  4. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of ...Read the original story

    Apr 22, 2015 | CiteULike

    Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.


  5. Treatment of progressive IgA nephropathy: an update.Read the original story

    Apr 18, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. IgA nephropathy is the most common primary glomerular disease worldwide.


  6. Is newer safer? Adverse events associated with first-line therapies...Read the original story

    Apr 15, 2015 | CiteULike

    Clinical outcomes in ANCA-associated vasculitis and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events, most notably infections, cytopenias, malignancies, and reproductive abnormalities.


  7. Rituximab as Induction Therapy After Renal Transplantation: A...Read the original story

    Apr 15, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. We evaluated the efficacy and safety of rituximab as induction therapy in renal transplant patients.


  8. Aurinia Reports Fourth Quarter And Full Year 2014 Financial Results...Read the original story

    Mar 30, 2015 | BioSpace

    Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars.


  9. Evaluating the efficacy, safety and evolution of renal function with ...Read the original story

    Mar 25, 2015 | Trials Journal

    Background Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral infection and hepatocellular carcinoma.


  10. Glory Biotech Co., Ltd. (4187) - Financial and Strategic SWOT...Read the original story

    Mar 24, 2015 | PR-inside.com

    Glory Biotech Co., Ltd. is a biopharmaceutical company. The company develops and produces active pharmaceutical ingredients and healthcare foods from microorganism.


  11. Which dose of steroids and which cytotoxics for severe lupus?Read the original story

    Mar 24, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. There have been a number of major advances in the treatment of systemic lupus erythematosus and we are now in the era of biologic therapies for this multisystem autoimmune disorder.


  12. Maintenance therapy in antineutrophil cytoplasmic antibody-associated ...Read the original story

    Mar 23, 2015 | CiteULike

    Anti-neutrophil cytoplasmic autoantibody -associated vasculitides are severe chronic auto-immune diseases in which the small vessels are inflamed. Nowadays, in the majority of patients disease can be brought into remission with cyclophosphamide and corticosteroids.


  13. Comparison of non-myeloablative conditioning regimens for lymphoproliferative disordersRead the original story

    Mar 4, 2015 | Bone Marrow Transplantation

    Correspondence: Dr MC Pasquini, Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226, USA. E-mail: mpasquini@mcw.edu Hematopoietic cell transplantation with non-myeloablative conditioning for lymphoproliferative diseases includes fludarabine with and without low-dose TBI.


  14. Successful treatment of refractory childhood pemphgus vulgaris with...Read the original story

    Feb 21, 2015 | CiteULike

    Pediatric dermatology , Vol. 22, No. 5. , pp. 461-464, doi:10.1111/j.1525-1470.2005.00118.x To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.


  15. Aurinia To Initiate An Open Label Clinical Study To Investigate The...Read the original story

    Feb 8, 2015 | BioSpace

    Aurinia Pharmaceuticals Inc. today announced that it will initiate an open label, exploratory study to assess the short term predictors of response using voclosporin in combination with mycophenolate mofetil in patients with active lupus nephritis. AURION will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.


  16. Pharmacogenomics: Personalizing Pediatric Heart Transplantation...Read the original story

    Feb 2, 2015 | Circulation

    Correspondence to Steven A. Webber, James C. Overall Professor of Pediatrics, Chair, Department of Pediatrics, Vanderbilt University School of Medicine, Pediatrician-in-Chief, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN 37232. E-mail In recent years, outcomes for pediatric cardiac transplantation have steadily improved, with current 5-year overall survival rates estimated at 83%.


  17. Journal ClubRead the original story

    Jan 30, 2015 | Kidney International

    In kidney transplant recipients, persistent hypercalcemia and hypophosphatemia associated with hyperparathyroidism may complicate post-transplantation care by increasing the risk of fracture, vascular calcification, and renal allograft nephropathy. Satisfactory long-term management with loop diuretics and antiresorptive agents to correct hypercalcemia or phosphate supplements to correct hypophosphatemia is difficult to obtain and may be harmful.


  18. Pregnancy in renal transplant recipients.Read the original story

    Jan 27, 2015 | CiteULike

    Fertility in women with kidney failure is restored by transplantation. It requires careful planning and is only advisable in women with good kidney function, controlled blood pressure, and general good health.


  19. A neurologist's guide to safe use of immunomodulatory therapies.Read the original story

    Jan 12, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Increased understanding of the pathogenesis of immune-mediated neurologic conditions with concomitant development of new therapeutic agents modulating various aspects of the immune system has resulted in the use of innovative therapies in the treatment of these diseases.


  20. Insights into the role of genetic variants in kidney diseaseRead the original story w/Photo

    Jan 12, 2015 | Medical News Today

    New research provides insights into the ties between certain genetic variants and kidney disease in African Americans. The genetic association is one of the strongest ever reported for a common disease, and these latest findings may help improve diagnosis and treatment.